1. At a Glance – The Biotech With a Brewing Lab and a 39x Ego
₹1,184 per share. Market cap ₹12,391 Cr. Stock down 21% in 3 months and 30% in one year. And yet, this fermentation specialist is still flexing a 39x P/E like it owns the lab coat industry.
Concord Biotech Limited just posted Q3 FY26 revenue of ₹278 Cr (up 14% YoY), but PAT slipped 16% YoY to ₹64 Cr. EBITDA margin cooled to 35.6% from 40.1%. The management says, “Relax, it’s just injectable commercialization and US subsidiary setup costs.” Investors say, “Okay… but margins please?”
ROCE stands at a juicy 28.4%, ROE at 21.4%, debt almost zero (₹1.61 Cr), and interest coverage at a ridiculous 1,506x. This is basically a pharma company with a monk-level aversion to debt.
But here’s the real masala — fermentation-based APIs, global DMFs, USFDA approvals, WHO-GMP injectables, and a new US subsidiary. Sounds like a biotech flex. Yet the stock is correcting hard.
So what is Concord? A high-entry-barrier compounder temporarily sulking? Or a premium stock rediscovering gravity?
Let’s enter the lab.
2. Introduction – From One Molecule to a Multi-Product Fermentation Monster
Concord Biotech started in 1984. Back then, fermentation wasn’t trendy. It was complex, capital-intensive, and required patience. Basically, the opposite of today’s instant-IPO culture.
This Ahmedabad-based company built its empire on fermentation-based APIs — high-entry-barrier molecules used in immunosuppressants, oncology, antifungals, and anti-infectives.
Over time, it evolved:
- From single-product to multi-product.
- From APIs to formulations.
- From India to 70+ countries.
- From local supplier to USFDA/EMA/WHO compliant exporter.
Now, it has:
- 30+ fermentation APIs
- 100+ approved formulation products
- 140+ DMFs globally
- 1,250 m³ fermentation capacity
- 802 million units formulation capacity
And in March 2025, it started commercial production at its new injectable facility (Unit IV).
Question for you: How many Indian pharma companies can say they operate across API, formulations, AND CDMO — all under a fermentation umbrella?
Exactly.
3. Business Model – WTF Do They Even Do?
Let me simplify.
Step 1: They Brew Molecules
Fermentation is
